




RealRate

PHARMACEUTICAL 2017

Vistagen Therapeutics Inc. Rank 291 of 292



VistaGen®
Therapeutics



RealRate

The First AI Rating Agency

www.realrate.ai



RealRate

PHARMACEUTICAL 2017

Vistagen Therapeutics Inc. Rank 291 of 292



VistaGen®
Therapeutics

The relative strengths and weaknesses of Vistagen Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Vistagen Therapeutics Inc. compared to the market average is the variable Liabilities, Non-Current, increasing the Economic Capital Ratio by 327% points. The greatest weakness of Vistagen Therapeutics Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 1,851% points.

The company's Economic Capital Ratio, given in the ranking table, is -2,112%, being 2,115% points below the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	855
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,795
Liabilities, Non-Current	2,172
Other Assets	47
Other Compr. Net Income	0
Other Expenses	2,670
Other Liabilities	0
Other Net Income	-26,700
Other Revenues	0
Property and Equipment	88
Research and Development	3,932
Selling, General and Administrative Expense	13,919

Output Variable	Value in 1000 USD
Assets	990
Liabilities	3,967
Expenses	20,520
Revenues	0
Stockholders Equity	-2,977
Net Income	-47,220
Comprehensive Net Income	-47,220
Economic Capital Ratio	-2,112%